ZyVersa Therapeutics, Inc
Monday, February 26, 2024
Royale
Multiple Therapeutics
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. Our development pipeline includes clinical stage Cholesterol Efflux MediatorTM VAR 200 in development to alleviate damaging accumulation of cholesterol and lipids in the kidneys’ filtration system. The lead indication is treatment of rare kidney disease, focal segmental glomerulosclerosis. VAR 200 has potential to treat other kidney diseases, including Alport syndrome and diabetic kidney disease. ZyVersa’s pipeline also includes proprietary inflammasome ASC inhibitor IC 100 that blocks initiation and perpetuation of damaging inflammation associated with a multitude of inflammatory diseases. IC 100 has potential to treat many different CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.
State
Florida
Country
United States
Website
http://www.zyversa.com
CEO/Top Company Official
Steve Glover, Chairman and CEO
Lead Product in Development
Cholesterol Efflux Mediator VAR 200 for renal disease.
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
None. Our two development products were licensed from University of Miami.